Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis
- 13 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Urology and Nephrology
- Vol. 52 (4), 791-802
- https://doi.org/10.1007/s11255-020-02418-w
Abstract
Background The aim of this meta-analysis is to explore the effect of IL-2RA vs rATG on the rate of acute rejection, post-transplant infections, and graft as well as patient’s survival in standard- and high-risk renal transplant patients receiving tacrolimus-based maintenance immunotherapy. Methods Random effects model was the method used for identifying risk difference. Confidence interval including the value 1 was used as evidence for statistically significant risk difference. Heterogeneity was assessed using Der Simonian analysis. Heterogeneity was evident at the level of P value < 0.1 Results The random effects model showed no significant differences in both acute rejection rates between IL-2RA and rATG induction therapies with relative risk of 1.24 graft survival with relative risk 0.90. Patient survival also did not demonstrate any significant difference with a relative risk of 1.19. Random effects for CMV infection showed a lesser tendency for CMV infection in IL-2RA group compared to ATG group the with a relative risk of 0.73.In subgroup analysis, the random effects model for acute rejection rates in high-risk transplants showed a higher risk of acute rejection in the IL-2RA group compared to rATG (relative risk equals 1.55) In standard-risk transplants, there were no significant differences between both groups with relative risk equals 1.02 Conclusions This meta-analysis revealed no significant difference in patient and graft survival when using IL-2RA vs rATG with the tacrolimus-based maintenance immunosuppression era. However, subgroup analysis showed less incidence of rejection in high-risk renal transplant recipient’s population using rATG compared to IL-2RA.Keywords
This publication has 23 references indexed in Scilit:
- Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcomeSaudi Journal of Kidney Diseases and Transplantation, 2014
- Renal Association Clinical Practice Guideline on Post-operative Care of the Kidney Transplant RecipientNephron Clinical Practice, 2011
- Randomized Trial of Thymoglobulin Versus Alemtuzumab (with Lower Dose Maintenance Immunosuppression) Versus Daclizumab in Living Donor Renal TransplantationTransplantation Proceedings, 2010
- Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsAmerican Journal of Transplantation, 2009
- Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant RecipientsJournal of the American Society of Nephrology, 2009
- Anti–IL-2 Receptor Antibodies versus Anti-Thymocyte Globulin for Induction Therapy in Kidney TransplantationJournal of the American Society of Nephrology, 2009
- A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐upClinical Transplantation, 2007
- Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipientsCochrane Database of Systematic Reviews, 2005
- Renal Transplantation in Black AmericansNew England Journal of Medicine, 2000
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000